YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Cancer & Hypoxia Pathway Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a small-molecule inhibitor of hypoxia-inducible factor-1α (HIF-1α) and a soluble guanylyl cyclase (sGC) activator, with an IC50 of 1.2 µM for hypoxia-induced HIF-1 transcriptional activity (APExBIO, product page). It blocks HIF-1α at the post-transcriptional level, suppressing tumor survival, growth, and angiogenesis under hypoxic conditions. YC-1 is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but insoluble in water. In vitro, it inhibits platelet aggregation and vascular contraction via sGC activation, while in vivo, it reduces tumor vascularization and HIF-1α target gene expression. These properties make YC-1 a critical research tool for dissecting cancer, hypoxia, and cGMP signaling pathways (see comparison).

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor central to the cellular response to hypoxia. It regulates genes linked to angiogenesis, cell survival, and metastasis in solid tumors (APExBIO). Under normoxic conditions, HIF-1α is rapidly degraded. Under hypoxic conditions, HIF-1α accumulates, translocates to the nucleus, and activates transcription of genes such as VEGF, facilitating tumor vascularization and adaptation to low oxygen (see review). Inhibition of HIF-1α transcriptional activity disrupts this adaptation, impairing tumor growth and metastasis. Soluble guanylyl cyclase (sGC) is another key player, acting as the primary receptor for nitric oxide (NO) and modulating vascular tone and platelet function via the cyclic GMP (cGMP) pathway. YC-1 targets both HIF-1α and sGC, offering dual utility in cancer biology and vascular research.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 acts through two primary mechanisms:

• HIF-1α Inhibition: YC-1 inhibits HIF-1α at the post-transcriptional level, blocking its accumulation and subsequent transcriptional activity in hypoxic cells. This inhibition is independent of sGC activation and is linked to the oxygen-sensing pathway (APExBIO).
• sGC Activation: YC-1 directly activates soluble guanylyl cyclase, increasing cGMP levels and thereby inhibiting platelet aggregation and vascular contraction. This pathway is critical for cardiovascular research and complements its anticancer utility (see mechanism details).

These dual actions make YC-1 a unique research compound for probing the intersection of hypoxia, angiogenesis, and cGMP signaling in diverse experimental models.

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC50 of 1.2 µM in vitro (APExBIO, product page).
• YC-1-treated tumors in vivo are significantly smaller and less vascularized, with reduced HIF-1α and target gene expression (APExBIO, product page).
• YC-1 solubility is ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol at room temperature; it is insoluble in water (APExBIO, product page).
• In vitro, YC-1 inhibits platelet aggregation and vascular contraction through sGC activation (APExBIO, product page).
• Purity for research-grade YC-1 (SKU B7641) exceeds 98% by HPLC, ensuring reproducibility in experimental workflows (APExBIO, product page).
• YC-1 has been compared favorably to other HIF-1α inhibitors in workflow flexibility and reproducibility (see workflow guidance).

Applications, Limits & Misconceptions

YC-1 is used extensively in cancer research, hypoxia signaling studies, and cGMP pathway interrogation. Its dual action allows for precise modulation of tumor angiogenesis and vascular tone. However, its specificity for HIF-1α inhibition is context-dependent, and it is not suitable for clinical or diagnostic use. The compound is intended strictly for scientific research. Compared to other HIF-1α inhibitors, YC-1 offers higher solubility and workflow flexibility, though careful attention to solvent systems is required for maximal efficacy (see protocol update).

Common Pitfalls or Misconceptions

• YC-1 is not water-soluble; attempts to dissolve in aqueous buffers will result in precipitation and loss of activity.
• YC-1 is not a clinical drug and is not approved for diagnostic or therapeutic use in humans.
• Its sGC activation does not directly equate to HIF-1α inhibition; the two mechanisms are independent.
• Prolonged storage of YC-1 solutions (especially in DMSO or ethanol) is not recommended due to potential degradation; solutions should be prepared fresh.
• It may not inhibit HIF-1α effectively in non-hypoxic models or where HIF-1α is regulated by alternate pathways.

Workflow Integration & Parameters

YC-1 should be dissolved in DMSO (≥30.4 mg/mL) or ethanol (≥16.2 mg/mL) immediately before use. For cell-based assays, working concentrations typically range from 0.5 to 10 µM, depending on cell type and endpoint. Solutions should be used promptly after preparation to avoid hydrolysis or oxidation. The crystalline solid should be stored at room temperature and protected from moisture. For in vivo work, dosing and formulation require adjustment to ensure bioavailability in animal models. Detailed protocols are available from APExBIO and recent literature (see protocol comparisons). This article clarifies the solvent compatibility, workflow timing, and purity standards relative to earlier guides, enabling reproducible hypoxia and cancer biology experiments.

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol provides a robust, dual-action tool for interrogating hypoxia signaling, tumor angiogenesis, and cGMP pathways. Its high purity, solubility, and validated inhibitory profile make it preferable to less well-characterized HIF-1α inhibitors. As research into the molecular basis of cancer and hypoxia adapts, YC-1 supplied by APExBIO will continue to support methodologically rigorous studies. For further product details or to order, see the official YC-1 product page.